33609 - CXCL10 (plasma)
Cytokines and chemokines play critical roles in regulating innate and adaptive immune responses. Quantitative assessment of immune signaling biomarkers can provide insight into inflammatory pathways associated with immune activation.
About Test
CXCL10 (also known as Interferon Gamma-Induced Protein 10 [IP-10]) is an IFN-γ-inducible chemokine that shares the CXCR3 receptor with CXCL9 and acts as a potent chemoattractant for activated T cells, NK cells, and dendritic cells. It is a well-characterized marker of Th1-polarized immune responses and is elevated across a range of inflammatory states relevant to transplant recipients and hematology-oncology patients.
ProcedureQuantitative Multiplex Fluorescence Immunoassay. This test was developed and its performance characteristics were determined by Eurofins Viracor. This test has not been cleared or approved for diagnostic use by the U.S. Food and Drug Administration.
Specificity≤2% off-target recovery when tested using samples individually spiked with 1200, 760, & 400 pg/mL CXCL9 or 3000, 2000, & 1200 pg/mL IL-18
24 hours from receipt of specimen. To meet the 24-hour turnaround time, test orders will need to be received at the lab by 11am CST. Monday - Saturday.
| Specimen Type | Test Code | CPT Code | NY Approved | Volume | Assay Range | Special Instructions |
|---|---|---|---|---|---|---|
| plasma | 33609 | 83520 | No | 1 mL (min. 200 uL) |
91 - 22009 pg/mL |
|
The reference range for a healthy population is less than 91 pg/mL The reference range for this assay was determined from a population of healthy adults.
Specimens are approved for testing in New York only when indicated in the Specimen Information field above. The CPT codes provided are based on Eurofins Viracor’s interpretation of the American Medical Association's Current Procedural Terminology (CPT) codes and are provided for informational purposes only. CPT coding is the sole responsibility of the billing party. Questions regarding coding should be addressed to your local Medicare carrier. Eurofins Viracor assumes no responsibility for billing errors due to reliance on the CPT codes illustrated in this material.
References- Goutaudier V, et al. Detection of Kidney Allograft Rejection Using Urinary Chemokines. J Am Soc Nephrol. 2025;36(11):2228-2240. https://doi.org/10.1681/ASN.0000000742
- Macinioniene E, et al. Urinary Chemokines CXCL9 and CXCL10 Are Non-Invasive Biomarkers of Kidney Transplant Rejection. Ann Transplant. 2024;29:e944762. https://doi.org/10.12659/AOT.944762
- Tinel C, et al. Transforming kidney transplant monitoring with urine CXCL9 and CXCL10: practical clinical implementation. Sci Rep. 2024;14(1):20357. https://doi.org/10.1038/s41598-024-70390-x
- Shino MY, et al. Plasma CXCL9 and CXCL10 at allograft injury predict chronic lung allograft dysfunction. Am J Transplant. 2022;22(9):2169-2179. https://doi.org/10.1111/ajt.17108
- Kim SC, Page EK, Knechtle SJ. Urine proteomics in kidney transplantation. Transplant Rev. 2014;28(1):15-20. https://doi.org/10.1016/j.trre.2013.10.004
- Zhuang J, et al. CXCL9 and CXCL10 accelerate acute transplant rejection mediated by alloreactive memory T cells. Exp Ther Med. 2014;8(1):237-242. https://doi.org/10.3892/etm.2014.1714
- Ciftci HS, et al. Urinary CXCL9 and CXCL10 Levels and Acute Renal Graft Rejection. Int J Organ Transplant Med. 2019;10(2):53-63. PMC6604756
- Dai H, et al. Polymorphisms in CXCR3 ligands predict early CXCL9 recovery and severe chronic GVHD. Blood Cancer J. 2021;11(2):42. https://doi.org/10.1038/s41408-021-00434-2
- Orsatti L, et al. Kynurenine pathway activation and deviation to anthranilic and kynurenic acid in fibrosing chronic GVHD. Cell Rep Med. 2021;2(10):100409. https://doi.org/10.1016/j.xcrm.2021.100409
- Moy RH, et al. Clinical and immunologic impact of CCR5 blockade in GVHD prophylaxis. Blood. 2017;129(7):906-916. https://doi.org/10.1182/blood-2016-08-735076